FDA again spells out safety concerns with oral type 1 diabetes drug while denying Lexicon's attempt to overturn a CRL

Back in March 2019, the FDA made clear to Sanofi and its partner Lexicon Pharmaceuticals — Sanofi has since left the picture — that it couldn …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA again spells out safe­ty con­cerns with oral type 1 di­a­betes drug while deny­ing Lex­i­con's at­tempt to over­turn a CRL